Evidence map›Paper›PMID 35283940›Full record

ArticleAfrican health sciences2021

COVID-19 in Africa: rethinking the tools to manage future pandemics.

Ismaila Emahi, Mimmie Cnc Watts, Samuel Azibere, Joseph F Morrison, Kwabena An Sarpong

Open access · diamondAbstract read
In one paragraph

Article in African health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ismaila EmahiDepartment of Chemical Sciences, University of Energy and Natural Resources, Sunyani, Ghana.
Mimmie Cnc WattsCollege of Health, Federation University, Melbourne Australia.
Samuel AzibereDepartment of Chemical Sciences, University of Energy and Natural Resources, Sunyani, Ghana.
Joseph F MorrisonTris Pharma, Inc, NJ, USA.
Kwabena An SarpongDepartment of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Ghana.
University of Energy and Natural Resources · GHUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corona virus disease 2019 (COVID-19) remains an incurable, progressive pneumonia-like illness characterized by fever, dry cough, fatigue, and headache during its early stages. COVID-19 has ultimately resulted in mortality in at least 2 million people worldwide. Millions of people globally have already been affected by this disease, and the numbers are expected to increase, perhaps until an effective cure or vaccine is identified. Although Africa was initially purported by the World Health Organization (WHO) to be severely hit by the pandemic, Africa recorded the least number of cases during the first wave, with lowest rates of infections, compared to Asia, Europe, and the Americas. This statistic might be attributed to the low testing capacity, existing public health awareness and lessons learnt during Ebola epidemic. Nonetheless, the relatively low rate of infection should be an opportunity for Africa to be better prepared to overcome this and future epidemics. In this paper, the authors provide insights into the dynamics and transmission of the severe acute respiratory syndrome corona virus (SARS-CoV-2) during the first wave of the pandemic; possible explanations into the relatively low rates of infection recorded in Africa; with recommendations for Africa to continue to fight Covid-19; and position itself to effectively manage future pandemics.

Indexed as

COVID-19PandemicsAfricaDisease OutbreaksHumansSARS-CoV-2Covid-19EbolaFuture PandemicsHealth leadershipPreventative HealthSARS-COV-2Science Leadership in AfricaVaccine

Identifiers

PMID35283940
PMCPMC8889828
OpenAlexW4200489248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.